Compare FedEx Corporation (FDX) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs Moderna, Inc. — how do they compare? FedEx Corporation trades at $291.71 (market cap $69.04B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: FedEx Corporation and Moderna, Inc. are close in size by market cap, and FedEx Corporation pays a 1.67% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold FedEx Corporation for 87 Days and Moderna, Inc. for 59 Days on average.
| FDX | MRNA | |
|---|---|---|
Market Cap | $69.04B | $78.65B |
Volume | 1,287,367 | 37,373,437 |
Sector | Industrials | Health |
52-Week High | $339.35 | $203.46 |
52-Week Low | $180.87 | $22.36 |
Typical Hold Time | 87 Days | 59 Days |
Enterprise Value | $98.68B | $74.80B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FedEx (FDX) trades at $291.73, up 0.93% today, with a bearish technical signal but strong fundamentals including a P/E of 15.73 and net income margin of 4.68%. Recent earnings beats in Q4 2025 and Q1 2026 highlight operational strength, while news includes a $300 million electric truck order and shareholder approval of executive pay. Cash flow trends show a projected rebound in 2026 to $7.8 billion net.
The outlook is mixed: analyst consensus is bullish with a $307.55 price target, but rising fuel costs and net cash outflows pose risks. Investment appeal lies in valuation discounts and dividend yield, though bearish technicals and economic sensitivity warrant caution for near-term volatility.
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
